nach oben

Erschienen in:

01.07.2015 | Urology - Original Paper

Urine chemokines indicate pathogenic association of obesity with BPH/LUTS

verfasst von: Pradeep Tyagi, Saundra S. Motley, Mahendra Kashyap, Subrata Pore, Jeffrey Gingrich, Zhou Wang, Naoki Yoshimura, Jay H. Fowke

Erschienen in: International Urology and Nephrology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Objectives

High prevalence of lower urinary tract symptoms (LUTS) consistent with benign prostate hyperplasia (BPH) is associated with obesity and prostatic inflammation. Here, we investigated whether chemokines associated with obesity and prostatic inflammation can be measured in normally voided urine of BPH/LUTS patients to demonstrate the mechanistic association between obesity and BPH/LUTS.

Methods

Frozen urine specimens of BPH/LUTS patients enrolled in the Nashville Men’s Health Study were sent for blinded analysis to University of Pittsburgh. Thirty patients were blocked by their AUA-SI (>7 or ≤7) and prostatic enlargement (<40, 40–60, >60 cc). Clinical parameters including age, prostate size, and medications were derived from chart review. CXC chemokines (CXCL-1, CXCL-8, and CXCL-10), CC chemokines (CCL2 and CCL3), and sIL-1ra were measured in thawed urine using Luminex™ xMAP^® technology and ELISA for NGF.

Results

Urinary CCL2 levels were several fold higher compared with the other six proteins, of which CCL3 was detectable in less than one-fourth of patients. Urine levels of sIL-1ra and CXCL-8 were significantly associated with increasing BMI and waist circumference in BPH patients. CXCL-8 showed a marginal association with overall AUA-SI scores, as well as obstructive (p = 0.08) symptom subscores. Prostate volume was inversely and marginally associated with urinary CXCL-10 (p = 0.09).

Conclusions

Urine levels of CXCL-8, CXCL-10, and sIL-1ra were associated with varying degrees with LUTS severity, prostate size, and obesity, respectively. These findings in urine are consistent with past studies of chemokine levels from expressed prostatic secretions and demonstrate the potential of noninvasively measured chemokine in urine to objectively classify BPH/LUTS patients.

Michel M, de la Rosette J (2009) Medical treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Euro Urol Suppl 8(6):496–503CrossRef

Roehrborn CG (2008) BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 101(Suppl 3):17–21. doi:10.1111/j.1464-410X.2008.07497.x PubMedCrossRef

St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ (2006) Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 164(8):760–768. doi:10.1093/aje/kwj258 PubMedCrossRef

Raheem OA, Parsons JK (2014) Associations of obesity, physical activity and diet with benign prostatic hyperplasia and lower urinary tract symptoms. Curr Opin Urol 24(1):10–14. doi:10.1097/MOU.0000000000000004 PubMedCrossRef

Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW (2011) PPARgamma: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation 82(4–5):220–236. doi:10.1016/j.diff.2011.05.008 PubMedCentralPubMedCrossRef

Li HB, Jin C, Chen Y, Flavell RA (2014) Inflammasome activation and metabolic disease progression. Cytokine Growth Factor Rev 25(6):699–706. doi:10.1016/j.cytogfr.2014.07.020 PubMedCrossRef

Perez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, Schlondorff D (2001) Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 12(7):1369–1382PubMed

Macoska JA (2011) Chemokines and BPH/LUTS. Differentiation 82(4–5):253–260. doi:10.1016/j.diff.2011.04.003 PubMedCentralPubMedCrossRef

Tyagi P, Killinger K, Tyagi V, Nirmal J, Chancellor M, Peters KM (2012) Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol 187(6):2243–2248. doi:10.1016/j.juro.2012.01.034 PubMedCentralPubMedCrossRef

10.

Hung SF, Chung SD, Kuo HC (2014) Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS ONE 9(1):e85588. doi:10.1371/journal.pone.0085588 PubMedCentralPubMedCrossRef

11.

Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB, Pavlovich CP (2010) Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate 70(5):473–481. doi:10.1002/pros.21081 PubMed

12.

Penna G, Mondaini N, Amuchastegui S, Innocenti SD, Carini M, Giubilei G, Fibbi B, Colli E, Maggi M, Adorini L (2007) Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 51(2):524–533 discussion 533 PubMedCrossRef

13.

Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, Morelli A, Rastrelli G, Comeglio P, Sebastanelli A, Maneschi E, Nesi G, De Nunzio C, Tubaro A, Mannucci E, Carini M, Maggi M (2013) Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 73(8):789–800. doi:10.1002/pros.22623 PubMedCrossRef

14.

Tyagi P, Chancellor M, Kupelian V, Araujo A, Rosen R, McKinlay J (2011) Obesity, inflammation and overactive bladder: preliminary results from a pilot study of serum leptin and MCP-1 levels in men and women with and without OAB symptoms. J Urol 185(4, Supplement):e462–e463. doi:10.1016/j.juro.2011.02.763 CrossRef

15.

Wei JT, Calhoun E, Jacobsen SJ (2008) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 179(5 Suppl):S75–S80. doi:10.1016/j.juro.2008.03.141 PubMedCrossRef

16.

Cartier A, Bergeron J, Poirier P, Almeras N, Tremblay A, Lemieux I, Despres JP (2009) Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity. Ann Med 41(6):471–478. doi:10.1080/07853890903022801 PubMedCrossRef

17.

Weber K, Schilling JD (2014) Lysosomes integrate metabolic-inflammatory cross-talk in primary macrophage inflammasome activation. J Biol Chem 289(13):9158–9171. doi:10.1074/jbc.M113.531202 PubMedCentralPubMedCrossRef

18.

Konwar R, Gara R, Singh M, Singh V, Chattopadhyay N, Bid HK (2008) Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology 71(5):868–872. doi:10.1016/j.urology.2007.12.072 PubMedCrossRef

19.

Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee C, Marberger M (2002) Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 52(1):43–58. doi:10.1002/pros.10084 PubMedCrossRef

20.

Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, Paikl D, Ecker RC, Hrachowitz K, Kramer G, Lee C, Marberger M (2003) Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 83(8):1131–1146PubMedCrossRef

21.

Lotti F, Corona G, Colpi GM, Filimberti E, Degli Innocenti S, Mancini M, Baldi E, Noci I, Forti G, Adorini L, Maggi M (2011) Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility. J Endocrinol Invest 34(10):e336–e342. doi:10.3275/7855 PubMed

22.

Antoniou KM, Tzanakis N, Tzortzaki EG, Malagari K, Koutsopoulos AV, Alexandrakis M, Wells AU, Siafakas NM (2008) Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients. Pulm Pharmacol Ther 21(6):840–844. doi:10.1016/j.pupt.2008.06.005 PubMedCrossRef

23.

Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV (2008) Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate 68(4):442–452. doi:10.1002/pros.20717 PubMedCrossRef

24.

Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR (2008) Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 72(1):205–213. doi:10.1016/j.urology.2007.11.083 PubMedCentralPubMedCrossRef

25.

Feneley MR, Span PN, Schalken JA, Harper M, Griffiths K, Holmes K, Kirby RS (1999) A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2(5/6):277–281. doi:10.1038/sj.pcan.4500377 PubMedCrossRef

26.

Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA (2012) CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS ONE 7(11):e49278. doi:10.1371/journal.pone.0049278 PubMedCentralPubMedCrossRef

27.

Bjork J, Grubb A, Larsson A, Hansson LO, Flodin M, Sterner G, Lindstrom V, Nyman U (2014) Accuracy of GFR estimating equations combining standardized cystatin C and creatinine assays: a cross-sectional study in Sweden. Clin Chem Lab Med. doi:10.1515/cclm-2014-0578 PubMed

28.

Bouchelouche K, Alvarez S, Andersen L, Nordling J, Horn T, Bouchelouche P (2004) Monocyte chemoattractant protein-1 production by human detrusor smooth muscle cells. J Urol 171(1):462–466PubMedCrossRef

29.

Desireddi NV, Campbell PL, Stern JA, Sobkoviak R, Chuai S, Shahrara S, Thumbikat P, Pope RM, Landis JR, Koch AE, Schaeffer AJ (2008) Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome. J Urol 179(5):1857–1861. doi:10.1016/j.juro.2008.01.028 discussion 1861–1852 PubMedCentralPubMedCrossRef

30.

Vicentini C, Gravina GL, Angelucci A, Pascale E, D’Ambrosio E, Muzi P, Di Leonardo G, Fileni A, Tubaro A, Festuccia C, Bologna M (2004) Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia. J Cancer Res Clin Oncol 130(4):217–221. doi:10.1007/s00432-003-0525-8 PubMedCrossRef

Titel: Urine chemokines indicate pathogenic association of obesity with BPH/LUTS
verfasst von: Pradeep Tyagi
Saundra S. Motley
Mahendra Kashyap
Subrata Pore
Jeffrey Gingrich
Zhou Wang
Naoki Yoshimura
Jay H. Fowke
Publikationsdatum: 01.07.2015
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 7/2015
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-015-0992-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2015

Hypofractionated radiation therapy for treatment of bladder carcinoma in patients aged 90 years and more: A new paradigm to be explored?

Angiomyolipoma being surgically excised for presumed kidney carcinoma

Expression of bone morphogenetic proteins 4, 6 and 7 is downregulated in kidney allografts with interstitial fibrosis and tubular atrophy

Risk factors for severe hypocalcemia after parathyroidectomy in prevalent dialysis patients with secondary hyperparathyroidism

Relationship of adiponectin to markers of oxidative stress in type 2 diabetic patients: influence of incipient diabetes-associated kidney disease